4.10 A Deep Dive into CheckMate 649 with Dr. Jeffrey Bien


Episode 4.10 Show Notes

Today we sit down (in person!) with Dr. Jeff Bien of Stanford University to break down all the details -- from the methods to the statistical analysis to the conclusions -- of the CheckMate 649 trial, which pitted first-line nivolumab plus chemotherapy against chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma.


Previous
Previous

4.11 CheckMate 274, PARADIGM-HF/Ernesto, POLO, & an AI Approach to Reducing Knee Pain

Next
Next

4.09 Problems with the VISION Trial & Stool Transplant Plus Nivo for Metastatic Melanoma